IGFBP2 and adenocarcinoma: Jianhua Zhou et al. 7 have reported that expression of IGFBP2 was observed in both squamous cell lung cancers and adenocarcinomas in 110 NSCLC patients, whereas the positive rate in adenocarcinoma was significantly higher than that in squamous cell carcinoma.